Literature DB >> 11112149

Fibroblast contractility: usual interstitial pneumonia and nonspecific interstitial pneumonia.

H Miki1, T Mio, S Nagai, Y Hoshino, T Nagao, M Kitaichi, T Izumi.   

Abstract

The aim of this study was to compare the function of lung fibroblasts obtained from surgically biopsied specimens of patients with idiopathic pulmonary fibrosis/usual interstitial pneumonia (UIP; n = 5), nonspecific interstitial pneumonia (NSIP; n = 5), and normal parts of surgically resected lungs (control; n = 5). The results showed that (1) fibroblasts obtained from UIP showed increased contractility compared with those obtained from NSIP or controls (UIP, 72.7 +/- 6.21%; NSIP, 32.8 +/- 5.46; controls, 28.5 +/- 3.51, p < 0.01 in UIP versus NSIP or control); (2) this increase in contractility was consistent with enhanced F-actin content in fibroblasts; (3) conditioned media from UIP fibroblast cultures enhanced control fibroblast contractility, whereas those obtained from NSIP or controls did not; (4) the 180 and 25 kD products representing the contractility in conditioned media were identified as fibronectin (ED-A domain) and TGF-beta1 by immunoblots, respectively; (5) the UIP-conditioned media contained higher amounts of fibronectin or TGF-beta 1 (fibronectin: UIP 289 +/- 47.1 ng/ml, NSIP 121 +/- 23.0, control 118 +/- 16.0; TGF-beta1: UIP 798 +/- 119 pg/ml, NSIP 246 +/- 69.1, control 247 +/- 53.6, p < 0.01 in UIP versus NSIP or control); () the contractility positively correlated with the amount of either fibronectin (r = 0.867, p < 0.001, n = 15) or TGF-beta 1 (r = 0.939, p < 0.001, n = 15), respectively. Thus, UIP fibroblasts showed greater contractility than did NSIP fibroblasts and up-regulated control fibroblasts.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11112149     DOI: 10.1164/ajrccm.162.6.9812029

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  11 in total

Review 1.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 2.  Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis.

Authors:  Eric S White; Michael H Lazar; Victor J Thannickal
Journal:  J Pathol       Date:  2003-11       Impact factor: 7.996

3.  Matrices of physiologic stiffness potently inactivate idiopathic pulmonary fibrosis fibroblasts.

Authors:  Aleksandar Marinković; Fei Liu; Daniel J Tschumperlin
Journal:  Am J Respir Cell Mol Biol       Date:  2013-04       Impact factor: 6.914

4.  Transforming growth factor-β1 downregulates vascular endothelial growth factor-D expression in human lung fibroblasts via the Jun NH2-terminal kinase signaling pathway.

Authors:  Ye Cui; Juan C Osorio; Cristobal Risquez; Hao Wang; Ying Shi; Bernadette R Gochuico; Danielle Morse; Ivan O Rosas; Souheil El-Chemaly
Journal:  Mol Med       Date:  2014-03-20       Impact factor: 6.354

5.  Prostacyclin analogs inhibit fibroblast contraction of collagen gels through the cAMP-PKA pathway.

Authors:  Koichiro Kamio; Xiangde Liu; Hisatoshi Sugiura; Shinsaku Togo; Tetsu Kobayashi; Shinsaku Kawasaki; Xingqi Wang; Lijun Mao; Youngsoo Ahn; Cory Hogaboam; Myron L Toews; Stephen I Rennard
Journal:  Am J Respir Cell Mol Biol       Date:  2007-03-15       Impact factor: 6.914

6.  Matrix metalloproteinase-9 activates TGF-β and stimulates fibroblast contraction of collagen gels.

Authors:  Tetsu Kobayashi; HuiJung Kim; Xiangde Liu; Hisatoshi Sugiura; Tadashi Kohyama; Qiuhong Fang; Fu-Qiang Wen; Shinji Abe; Xingqi Wang; Jeffrey J Atkinson; James M Shipley; Robert M Senior; Stephen I Rennard
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-04-04       Impact factor: 5.464

7.  Effect of montelukast, a cysteinyl receptor antagonist, on myofibroblasts in interstitial lung disease.

Authors:  Elizabeth Fireman; Yehuda Schwartz; Abraham Mann; Joel Greif
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

8.  C-type natriuretic peptide ameliorates pulmonary fibrosis by acting on lung fibroblasts in mice.

Authors:  Toru Kimura; Takashi Nojiri; Jun Hino; Hiroshi Hosoda; Koichi Miura; Yasushi Shintani; Masayoshi Inoue; Masahiro Zenitani; Hiroyuki Takabatake; Mikiya Miyazato; Meinoshin Okumura; Kenji Kangawa
Journal:  Respir Res       Date:  2016-02-19

9.  Development of a Three-Dimensional Bioengineering Technology to Generate Lung Tissue for Personalized Disease Modeling.

Authors:  Dan C Wilkinson; Jackelyn A Alva-Ornelas; Jennifer M S Sucre; Preethi Vijayaraj; Abdo Durra; Wade Richardson; Steven J Jonas; Manash K Paul; Saravanan Karumbayaram; Bruce Dunn; Brigitte N Gomperts
Journal:  Stem Cells Transl Med       Date:  2016-09-15       Impact factor: 6.940

10.  Quantitative Evaluation of Fibrosis in IPF Patients: Meaning of Diffuse Pulmonary Ossification.

Authors:  Monica Palermo; Francesco Tiralongo; Giulio Distefano; Ada Vancheri; Mauro Giuffrè; Fabio Pino; Pietro Valerio Foti; Gianluca Sambataro; Carlo Vancheri; Stefano Palmucci; Antonio Basile
Journal:  Diagnostics (Basel)       Date:  2021-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.